Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLAMINGO-01 phase 3 trial of GLSI-100 in HER2-positive breast cancer after trastuzumab-based therapy
2023-504323-25-01Phase 3Authorised
- Sponsor
- Greenwich LifeSciences, Inc.
- Start
- Mar 2024
- Modality
- Vaccines & Immunotherapeutics, Peptides, Recombinant Proteins and Enzymes
- Countries
- 15
01
Overview
Phase 3, randomised trial in breast cancer comparing GLSI-100 + sargramostim with Placebo control (2 arms). Primary endpoint: Invasive breast cancer-free survival. Planned start Mar 2024; status: authorised.
02
Drugs
GP2 peptidesargramostim
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-504323-25-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504323-25-01.